IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PECORELLI, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.293
AS - Asia 5.586
EU - Europa 4.655
SA - Sud America 1.052
AF - Africa 116
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 14
AN - Antartide 1
Totale 25.733
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.105
CN - Cina 2.151
SG - Singapore 1.725
UA - Ucraina 1.313
BR - Brasile 860
IT - Italia 662
DE - Germania 635
HK - Hong Kong 577
PL - Polonia 428
FI - Finlandia 427
VN - Vietnam 334
FR - Francia 295
GB - Regno Unito 246
TR - Turchia 209
IN - India 202
IE - Irlanda 195
RU - Federazione Russa 182
CA - Canada 120
BD - Bangladesh 81
SE - Svezia 77
AR - Argentina 68
IQ - Iraq 52
MX - Messico 44
NL - Olanda 36
JP - Giappone 35
ZA - Sudafrica 35
ID - Indonesia 34
EC - Ecuador 32
ES - Italia 30
VE - Venezuela 30
SA - Arabia Saudita 25
EE - Estonia 24
BE - Belgio 21
AT - Austria 19
MU - Mauritius 19
LT - Lituania 18
PK - Pakistan 18
MA - Marocco 17
EU - Europa 16
CL - Cile 15
AE - Emirati Arabi Uniti 14
CO - Colombia 14
AU - Australia 13
UZ - Uzbekistan 13
IR - Iran 12
PY - Paraguay 12
CZ - Repubblica Ceca 11
NP - Nepal 11
UY - Uruguay 11
IL - Israele 9
KG - Kirghizistan 9
TN - Tunisia 9
AZ - Azerbaigian 8
KE - Kenya 8
KZ - Kazakistan 8
NG - Nigeria 8
JO - Giordania 7
KR - Corea 7
TW - Taiwan 7
EG - Egitto 6
JM - Giamaica 6
PE - Perù 6
CR - Costa Rica 5
DZ - Algeria 5
PT - Portogallo 5
AL - Albania 4
BH - Bahrain 4
BO - Bolivia 4
CH - Svizzera 4
LK - Sri Lanka 4
MY - Malesia 4
OM - Oman 4
PS - Palestinian Territory 4
RO - Romania 4
TH - Thailandia 4
BB - Barbados 3
BG - Bulgaria 3
GE - Georgia 3
GR - Grecia 3
LU - Lussemburgo 3
LV - Lettonia 3
PH - Filippine 3
BY - Bielorussia 2
ET - Etiopia 2
GA - Gabon 2
LB - Libano 2
PR - Porto Rico 2
AO - Angola 1
AQ - Antartide 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BW - Botswana 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
HN - Honduras 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
MD - Moldavia 1
Totale 25.720
Salva come PNG Salva come JPEG
Città #
Fairfield 1.663
Woodbridge 1.636
Ashburn 1.267
Houston 1.123
Singapore 939
Jacksonville 916
Ann Arbor 800
Wilmington 764
Seattle 702
Cambridge 645
Hong Kong 556
Warsaw 421
San Jose 394
Beijing 386
Chandler 364
Nanjing 354
Princeton 353
New York 310
The Dalles 302
Los Angeles 224
Dearborn 212
Helsinki 212
Dublin 195
Istanbul 163
Lauterbourg 155
Nanchang 128
Ho Chi Minh City 125
Des Moines 117
Moscow 100
San Diego 90
Shenyang 87
São Paulo 83
Changsha 76
Milan 72
Munich 72
Shanghai 70
Buffalo 68
San Francisco 68
Hebei 67
Kunming 67
Hanoi 63
Jinan 60
Jiaxing 59
Redondo Beach 58
Chicago 55
Tianjin 55
Toronto 54
Brescia 50
Orem 50
Hangzhou 45
London 43
Dallas 39
Santa Clara 38
Chennai 31
Verona 30
Tokyo 29
Turku 29
Indianapolis 28
Montreal 28
Zhengzhou 28
Denver 25
Ningbo 25
Rio de Janeiro 25
Rome 24
Tallinn 24
Nuremberg 23
Belo Horizonte 22
Hefei 22
Brasília 20
Lanzhou 20
Monmouth Junction 20
Stockholm 20
Brooklyn 19
Brussels 19
Council Bluffs 19
Guangzhou 19
Lancaster 19
Washington 19
Taizhou 18
Amsterdam 17
Atlanta 17
Charlotte 17
Mexico City 17
Mumbai 17
Poplar 17
Porto Alegre 17
Pune 17
Baghdad 16
Dong Ket 16
Frankfurt am Main 16
Johannesburg 16
Norwalk 16
Orange 16
Phoenix 16
Boston 14
Central 14
Dhaka 14
Manchester 14
Paris 14
Campinas 13
Totale 17.951
Salva come PNG Salva come JPEG
Nome #
Bambini pretermine: nati per vivere 360
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 351
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 329
Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in adolescents in Northern Italy: an observational school-based study. 313
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 286
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. 223
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor 222
OVEREXPRESSION OF CLOSTRIDIUM PERFRINGENS ENTEROTOXIN RECEPTORS CLAUDIN-3 AND CLAUDIN-4 IN UTERINE CARCINOSARCOMAS. 221
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 219
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 208
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 202
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin 202
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 198
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 198
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 198
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 194
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas 190
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). 188
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 187
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 185
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. 184
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 182
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women 182
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 181
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 177
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 176
DEVELOPMENT AND THERAPEUTIC EFFECT OF ADOPTIVELY TRANSFERRED T CELLS PRIMED BY TUMOR LYSATE-PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ENDOMETRIAL CANCER. 174
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 174
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 174
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 172
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 172
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 168
Chlamydia trachomatis genotypes in school adolescents, Italy 168
Consolidation therapies revisited: weekly paclitaxel 168
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 168
Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency 167
Mammaglobin B expression in human endometrial cancer 165
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). 164
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. 164
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody 163
Carcinoma of the Fallopian tube 163
Strategies to Improve Medication Adherence in Older Persons: Consensus Statement from the Senior Italia Federanziani Advisory Board 162
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. 161
ADVANCES IN DENDRITIC-CELL-BASED THERAPEUTIC VACCINES FOR CERVICAL CANCER. 161
TUMOR-INFILTRATING LYMPHOCYTES CONTAIN HIGHER NUMBERS OF TYPE 1 CYTOKINE EXPRESSORS AND DR+ T CELLS COMPARED WITH LYMPHOCYTES FROM TUMOR DRAINING LYMPH NODES AND PERIPHERAL BLOOD IN PATIENTS WITH CANCER OF THE UTERINE CERVIX. 158
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 158
Toward appropriate criteria in medication adherence assessment in older persons: Position Paper 157
Racial differences in overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in Uterine Serous Papillary Cancer 156
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. 156
Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model 156
Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor 155
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference 155
Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. 154
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer 152
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 152
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. 151
Early stage cervical cancer: adjuvant treatment in negative lymph node cases. 151
Carcinoma of the corpus uteri 151
Carcinoma of the Fallopian tube 150
Prescription drug use among older adults in Italy: A country-wide perspective 148
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcomas cell lines is linked to tubulin-beta-III expression. 147
Claudin-7 expression in human epithelial ovarian cancer 147
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer 146
HPV vaccination acceptability in young boys 146
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) 146
Revised FIGO staging for carcinoma of the vulva, cervix, andendometrium. 144
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 144
IN VITRO INDUCTION OF TUMOR-SPECIFIC HUMAN LYMPHOCYTE ANTIGEN CLASS I-RESTRICTED CD8 CYTOTOXIC T LYMPHOCYTES BY OVARIAN TUMOR ANTIGEN-PULSED AUTOLOGOUS DENDRITIC CELLS FROM PATIENTS WITH ADVANCED OVARIAN CANCER. 143
INDUCTION OF OVARIAN TUMOR-SPECIFIC CD CYTOTOXIC T LYMPHOCYTES BY ACID-ELUTED PEPTIDE-PULSED AUTOLOGOUS DENDRITIC CELLS 143
Mental health and the global agenda. 143
Scaling up health knowledge at European level requires sharing integrated data: An approach for collection of database specification 143
Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy 141
Replacement therapy for breast cancer survivors. A pilot study 141
Early stage ovarian cancer: the Italian contribution to clinical research. An update 141
Histological features of uteroplacental vessels in normal and hypertensive patients in relation to birthweight 140
High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA) 140
Hearing loss and cognitive decline in older adults: Questions and answers 140
Interval Cytoreduction in Ovarian Cancer 138
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. 138
Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 137
Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS) 137
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. 136
Staging classification for cancer of the ovary, fallopian tube, and peritoneum 136
Carcinoma of the fallopian tube. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 135
Interventional tools to improve medication adherence: Review of literature 135
New development of the FIGO staging system. 134
INCREASED LEVELS OF INTERLEUKIN-10 AND TRANSFORMING GROWTH FACTOR-BETA IN THE PLASMA AND ASCITIC FLUID OF PATIENTS WITH ADVANCED OVARIAN CANCER. 134
Interval debulking surgery in advanced epithelial ovarian cancer 134
Gestational trophoblastic diseases 134
Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 133
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. 132
Carcinoma of the corpus uteri 130
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. 129
History of the FIGO cancer staging system 129
PHENOTYPIC AND FUNCTIONAL ANALYSIS OF TUMOR-INFILTRATING LYMPHOCYTES COMPARED WITH TUMOR-ASSOCIATED LYMPHOCYTES FROM ASCITIC FLUID AND PERIPHERAL BLOOD LYMPHOCYTES IN PATIENTS WITH ADVANCED OVARIAN CANCER. 128
EXPRESSION PATTERN AND MOLECULAR FUNCTION OF TRASCRIPTION FACTOR FOXM1 (FORKHEAD BOX PROTEIN M1) IN EPITHELIAL OVARIAN CANCER CLINICAL SPECIMENS AND CELL LINES 128
Cancer-related anemia: pathogenesis, prevalence and treatment. 126
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. 126
Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administrationof Clostridium perfringens enterotoxin. 126
Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium 126
Totale 16.700
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.176
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.176
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021619 0 0 0 0 0 0 0 0 0 263 271 85
2021/20221.537 124 236 13 71 11 106 77 88 77 292 123 319
2022/20231.190 240 30 50 69 83 343 10 94 153 11 52 55
2023/20241.512 78 35 145 108 82 358 49 60 330 57 20 190
2024/20252.699 19 31 10 379 308 265 188 77 264 165 622 371
2025/20265.795 674 835 421 1.007 610 393 884 199 331 441 0 0
Totale 26.175